Cooper Consumer Health and Esserre Pharma Sign Licensing Partnership to Expand the Armolipid® Portfolio
Paris, France / Rome, Italy, 2 September 2026 – Cooper Consumer Health, a leading European consumer healthcare company, today announced the signing of a licensing agreement with Esserre Pharma to introduce Armolipid® Cholesterol Plus, a new generation formula developed to support proactive cholesterol management.
Developed by Esserre Pharma, the new formulation combines carefully selected ingredients inspired by the Mediterranean diet with a dual-mechanism approach to cholesterol management and cardiovascular health.
This partnership reinforces Cooper Consumer Health's commitment to providing healthcare professionals and consumers with effective, evidence-based nutraceuticals that support healthy cholesterol levels. It also strengthens the Armolipid® franchise, one of Europe's leading cholesterol management brands, trusted by healthcare professionals and supported by decades of scientific evidence.
"We are pleased to announce this collaboration with Esserre Pharma, whose scientific and clinical expertise closely aligns with our ambition for developing high-quality, science-based healthcare products supported by clinical evidence," said Bart Meermans, CEO of Cooper Consumer Health. "By bringing this new generation, clinically studied formula into the Armolipid® portfolio, we are further strengthening one of our leading brands and expanding access to trusted nutritional options that support proactive cholesterol management as part of a healthy lifestyle."
"This agreement is a source of great satisfaction for us and a meaningful recognition of the work carried out by the entire Esserre Pharma team; from R&D and marketing to our Nutra Advisors in the field," said Amedeo Squillace, CEO of Esserre Pharma. "Our partnership with Cooper Consumer Health demonstrates the value of our scientific expertise and our ability to develop innovative healthcare options recognized by leading international companies. It also enables us to continue investing in future innovation and further advance our Mediterranean Nutrition Science platform."
The partnership combines the complementary scientific, clinical and consumer health expertise of Esserre Pharma and Cooper Consumer Health with the established heritage and European reach of the Armolipid® brand. Together, the companies aim to shape the next generation of science led cholesterol management and expand access to trusted, clinically studied nutritional options for healthcare professionals and consumers across Europe
About Cooper Consumer Health
Cooper Consumer Health is a leading pure-play OTC consumer healthcare platform in Europe. The company develops, manufactures and distributes a broad portfolio of category-leading self-care brands with high consumer awareness and loyalty, serving more than 100,000 pharmacies and drugstores across Europe and beyond.
https://www.cooperconsumerhealth.com/
About Esserre Pharma
Esserre Pharma is an Italian company engaged in the research, development and marketing of parapharmaceutical products (food supplements, cosmetics, medical devices) in Italy and abroad. Its approach is built on the Mediterranean Nutrients for Life concept, which values the macro- and micronutrients typical of the Mediterranean diet and region, favoring a short and sustainable supply chain. Esserre owns the Mediterranean Nutrition Science™ technology platform, through which it develops the formulations marketed under the NutraMet™, Flomel™, Redulen™ and Improve™ brands.
